Carnick & Kubik’s AstraZeneca AZN Stock Holding History

Carnick & Kubik’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-25,650	Closed	-$1.66M	–	105
2014 Q1	$1.66M	Sell	25,650 -25	-0.1%	-$1.61K	1.58%	12
2013 Q4	$1.52M	Sell	25,675 -470	-2%	-$25.5K	1.38%	14
2013 Q3	$1.36M	Buy	26,145 +395	+2%	+$19.8K	2.08%	10
2013 Q2	$1.22M	Buy	+25,750	New	+$1.31M	1.5%	15

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Carnick & Kubik's AZN Position: Q2 2014 in Review

Carnick & Kubik sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 25,650 shares — an estimated $1.66M sold.

Carnick & Kubik first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $1.66M in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Carnick & Kubik reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Carnick & Kubik sold 25,650 AstraZeneca shares in Q2 2014, an estimated $1.66M.
Carnick & Kubik first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
Carnick & Kubik's AstraZeneca position peaked at $1.66M in Q1 2014.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Carnick & Kubik's 13F filing for Q2 2014, filed 5 Aug 2014.